Perceptive Advisors portfolio · Q3 2026
Perceptive Advisors LLC · CIK 0001224962 ·13F filings on SEC EDGAR
In Q3 2026, Perceptive Advisors LLC reported 108 positions worth $5.7B. Its largest holding was PRAX at 10.3% of the portfolio, and the top 10 made up 50%. Its largest new position was FRNM ($198.5M), and it sold out of NUVL.
- NEW 26
- ADD 15
- REDUCE 42
- EXIT 27
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 68 positions are grouped as one box.
Portfolio history
Q4 2025 to Q3 2026, 4 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
PRAX PRAXIS PRECISION MEDICINES I | 10.27% | $112.81 | $291.23 | +158.2% | $589.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 5.36% | $9.99 | $29.10 | +191.2% | $307.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 5.09% | $39.46 | $89.03 | +125.6% | $292.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 4.70% | — | — | — | $269.6M | |
CELC CELCUITY INC | 4.40% | $37.50 | $79.52 | +112.0% | $252.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 4.20% | $101.51 | $95.22 | -6.2% | $241.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 4.15% | $14.52 | $36.57 | +151.8% | $238.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 4.00% | $12.45 | $18.05 | +44.9% | $229.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASND ASCENDIS PHARMA A/S | 3.86% | $266.72 | $227.83 | -14.6% | $221.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TVTX TRAVERE THERAPEUTICS INC | 3.63% | $23.74 | $58.88 | +148.0% | $208.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 3.46% | $15.75 | $15.75 | 0.0% | $198.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 2.93% | $21.59 | $40.60 | +88.0% | $168M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INBX INHIBRX BIOSCIENCES INC | 2.25% | $24.45 | $100.08 | +309.4% | $129.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 2.22% | $18.68 | $23.71 | +26.9% | $127.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KARD KARDIGAN INC | 2.11% | $23.85 | $14.75 | -38.2% | $121M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGTX MEIRAGTX HOLDINGS PLC | 2.07% | $13.25 | $11.00 | -17.0% | $118.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 2.05% | $43.67 | $140.89 | +222.6% | $117.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMTX IMMATICS NV | 1.72% | $10.56 | $8.78 | -16.9% | $98.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZYME ZYMEWORKS INC | 1.64% | $19.18 | $26.49 | +38.1% | $93.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 1.56% | $20.79 | $83.29 | +300.5% | $89.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 1.55% | $143.15 | $205.26 | +43.4% | $88.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLDB SOLID BIOSCIENCES INC | 1.50% | $6.95 | $7.23 | +4.0% | $86.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 1.49% | $9.13 | $8.33 | -8.7% | $85.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVLN AVALYN PHARMA INC | 1.33% | $32.92 | $28.49 | -13.5% | $76.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 1.17% | $26.95 | $24.95 | -7.4% | $67.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WAT WATERS CORP | 1.03% | $439.39 | $439.39 | 0.0% | $59.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RGEN REPLIGEN CORP | 0.91% | $139.43 | $192.23 | +37.9% | $52.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AORT ARTIVION INC | 0.84% | $15.27 | $22.82 | +49.4% | $48.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANRO ALTO NEUROSCIENCE INC | 0.78% | $17.97 | $25.53 | +42.1% | $45M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRD OPUS GENETICS INC | 0.76% | $4.84 | $4.84 | 0.0% | $43.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLSCall SELLAS LIFE SCIENCES GROUP I | 0.64% | — | — | — | $36.9M |
LKFT LAKEFRONT BIOTHERAPEUTIC-ADR | 0.64% | $29.65 | $29.65 | 0.0% | $36.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABT ABBOTT LABORATORIES | 0.59% | $98.83 | $98.83 | 0.0% | $34.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLSM BLOSSOMHILL THERAPEUTICS INC | 0.59% | $18.64 | $18.64 | 0.0% | $33.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XBIPut SS SPDR S&P BIOTECH ETF | 0.55% | — | — | — | $31.5M |
OBIO ORCHESTRA BIOMED HOLDINGS IN | 0.55% | $10.64 | $6.22 | -41.6% | $31.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLSPut SELLAS LIFE SCIENCES GROUP I | 0.54% | — | — | — | $30.8M |
CRVS CORVUS PHARMACEUTICALS INC | 0.50% | $11.91 | $11.52 | -3.3% | $28.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 0.46% | $5.56 | $7.77 | +39.6% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANL ADLAI NORTYE GROUP LTD | 0.46% | $11.50 | $16.00 | +39.1% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MMED MINIMED GROUP INC | 0.45% | $19.47 | $19.47 | 0.0% | $25.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.44% | $2.65 | $2.72 | +2.5% | $25.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPP RAPPORT THERAPEUTICS INC | 0.42% | $31.46 | $33.60 | +6.8% | $24.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 0.39% | $39.13 | $39.13 | 0.0% | $22.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XFOR X4 PHARMACEUTICALS INC | 0.37% | $4.11 | $2.90 | -29.4% | $21.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.37% | $45.84 | $45.84 | 0.0% | $21.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.37% | $3.82 | $3.17 | -17.0% | $21M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 0.36% | $18.83 | $16.11 | -14.5% | $20.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EOLS EVOLUS INC | 0.34% | $5.46 | $8.00 | +46.5% | $19.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
YARW YARROW BIOSCIENCE INC | 0.32% | $22.52 | $22.52 | 0.0% | $18.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 0.31% | $24.48 | $33.78 | +38.0% | $17.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SCTX SCRIBE THERAPEUTICS INC | 0.30% | $18.40 | $18.40 | 0.0% | $16.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAUT NAUTILUS BIOTECHNOLOGY INC | 0.29% | $6.31 | $1.42 | -77.5% | $16.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.27% | $28.66 | $16.11 | -43.8% | $15.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.25% | — | — | — | $14.6M | |
SRZN SURROZEN INC | 0.25% | $27.40 | $32.18 | +17.5% | $14.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GRAL GRAIL INC | 0.24% | $140.12 | $140.12 | 0.0% | $13.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.23% | $19.02 | $11.76 | -38.2% | $13.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DHR DANAHER CORP | 0.23% | $190.48 | $221.55 | +16.3% | $13.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRTC IRHYTHM HOLDINGS INC | 0.23% | $143.84 | $113.66 | -21.0% | $12.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GH GUARDANT HEALTH INC | 0.22% | $130.67 | $178.36 | +36.5% | $12.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.21% | $2.47 | $0.87 | -64.8% | $12M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADPT ADAPTIVE BIOTECHNOLOGIES | 0.21% | $20.50 | $28.90 | +41.0% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MANE VERADERMICS INC | 0.20% | $121.23 | $121.23 | 0.0% | $11.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.20% | — | — | — | $11.7M | |
AXGN AXOGEN INC | 0.20% | $33.80 | $41.92 | +24.0% | $11.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EYPTPut EYEPOINT INC | 0.20% | — | — | — | $11.4M |
PALI PALISADE BIO INC | 0.20% | $2.35 | $1.35 | -42.6% | $11.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.18% | $15.04 | $14.59 | -3.0% | $10.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBNX BETA BIONICS INC | 0.18% | $18.64 | $18.98 | +1.8% | $10.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPTX SEAPORT THERAPEUTICS INC | 0.18% | $21.72 | $20.17 | -7.1% | $10.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENTX ENTERA BIO LTD | 0.17% | $2.91 | $2.91 | 0.0% | $10M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.17% | $117.07 | $85.48 | -27.0% | $9.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QURE UNIQURE NV | 0.17% | $33.29 | $24.16 | -27.4% | $9.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XERS XERIS BIOPHARMA HOLDINGS INC | 0.16% | $8.74 | $9.56 | +9.4% | $8.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RACD RESEARCH ALLIANCE CORP IV-A | 0.14% | $11.84 | $11.84 | 0.0% | $8.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAPR CAPRICOR THERAPEUTICS INC | 0.14% | $9.47 | $9.47 | 0.0% | $8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.14% | $26.42 | $20.59 | -22.1% | $7.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 0.13% | $92.50 | $99.02 | +7.0% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENGN ENGENE THERAPEUTICS INC | 0.12% | $1.73 | $2.00 | +15.6% | $7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLLN BILLIONTOONE INC CL A | 0.12% | $81.24 | $106.44 | +31.0% | $6.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGMB AGOMAB THERAPEUTICS NV | 0.12% | $10.49 | $11.10 | +5.8% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LONA LEONABIO INC | 0.12% | $6.49 | $3.57 | -45.0% | $6.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIIB BIOGEN INC | 0.11% | $216.06 | $225.88 | +4.5% | $6.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DMRA DAMORA THERAPEUTICS INC | 0.10% | $21.28 | $21.28 | 0.0% | $6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADRX ADARX PHARMACEUTICALS INC | 0.10% | $19.94 | $19.94 | 0.0% | $6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NVCT NUVECTIS PHARMA INC | 0.09% | $18.39 | $21.12 | +14.8% | $5.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OLMA OLEMA PHARMACEUTICALS INC | 0.09% | $8.64 | $8.64 | 0.0% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OCS OCULIS HOLDING AG | 0.07% | $17.59 | $9.34 | -46.9% | $4.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
UNH UNITEDHEALTH GROUP INC | 0.06% | $415.63 | $367.08 | -11.7% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MOBI MOBIA MEDICAL INC | 0.06% | $13.40 | $9.45 | -29.5% | $3.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMDW REVOLUTION MEDICINES INC-28 | 0.05% | $0.33 | $11.44 | +3,366.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.05% | — | — | — | $2.7M | |
OM OUTSET MEDICAL INC | 0.04% | $11.06 | $3.00 | -72.9% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBLL CERIBELL INC | 0.04% | $24.39 | $24.39 | 0.0% | $2.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EDSA EDESA BIOTECH INC | 0.04% | $5.23 | $4.21 | -19.5% | $2.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EYPTCall EYEPOINT INC | 0.04% | — | — | — | $2.4M |
BRVE BRAVEHEART BIO INC | 0.04% | $20.20 | $20.20 | 0.0% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OTLK OUTLOOK THERAPEUTICS INC | 0.03% | $1.59 | $0.57 | -63.9% | $1.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADGM ADAGIO MEDICAL HOLDINGS INC | 0.03% | $2.57 | $0.15 | -94.1% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADMA ADMA BIOLOGICS INC | 0.02% | $8.43 | $10.03 | +19.0% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPRX KIORA PHARMACEUTICALS INC | 0.02% | $2.63 | $2.56 | -2.7% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDLN MEDLINE INC-CL A | 0.02% | $42.00 | $34.70 | -17.4% | $971.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XGN EXAGEN INC | 0.02% | $3.00 | $8.13 | +171.0% | $934.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTB CONNECT BIOPHARMA HOLDINGS L | 0.02% | $2.82 | $1.10 | -61.0% | $872K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SGMT SAGIMET BIOSCIENCES INC-A | 0.01% | $9.88 | $9.88 | 0.0% | $668.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IBIT ISHARES BITCOIN TRUST ETF | 0.01% | $47.34 | $47.34 | 0.0% | $568.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENSC ENSYSCE BIOSCIENCES INC | 0.00% | $8.14 | $0.42 | -94.9% | $36K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price.
Changes in shares
Change in shares held vs Jun 30, 2026, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Jun 30, 2026 and not reported for Q3 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| NUVL NUVALENT INC-A | 2.93% | 1,580,505 | $195.2M | EXIT |
| APGE APOGEE THERAPEUTICS INC | 2.61% | 1,308,113 | $173.6M | EXIT |
| IONS IONIS PHARMACEUTICALS INC | 0.67% | 566,000 | $44.9M | EXIT |
| JAZZ JAZZ PHARMACEUTICALS PLC | 0.61% | 170,000 | $41M | EXIT |
| SION SIONNA THERAPEUTICS INC | 0.60% | 905,000 | $39.8M | EXIT |
| CORT CORCEPT THERAPEUTICS INC | 0.52% | 398,385 | $34.6M | EXIT |
| 36322Q206 DAMORA THERAPEUTICS INC | 0.48% | 1,223,000 | $31.8M | EXIT |
| CRL CHARLES RIVER LABORATORIES | 0.48% | 140,000 | $31.8M | EXIT |
| AXSM AXSOME THERAPEUTICS INC | 0.44% | 118,450 | $29M | EXIT |
| TENX TENAX THERAPEUTICS INC | 0.37% | 1,700,000 | $24.7M | EXIT |
| CAPRCall CAPRICOR THERAPEUTICS INC | 0.36% | 1,000,000 | $24.1M | EXIT |
| ISRG INTUITIVE SURGICAL INC | 0.31% | 51,884 | $20.6M | EXIT |
| CTNM CONTINEUM THERAPEUTICS INC-A | 0.31% | 1,255,592 | $20.6M | EXIT |
| OMDA OMADA HEALTH INC | 0.26% | 786,330 | $17.3M | EXIT |
| CAPRPut CAPRICOR THERAPEUTICS INC | 0.18% | 500,000 | $12M | EXIT |
| OSCR OSCAR HEALTH INC - CLASS A | 0.17% | 400,000 | $11.4M | EXIT |
| BSX BOSTON SCIENTIFIC CORP | 0.16% | 250,000 | $10.7M | EXIT |
| NTRA NATERA INC | 0.14% | 34,689 | $9.4M | EXIT |
| RACC RESEARCH ALLIANCE CORP CL A | 0.12% | 750,000 | $8M | EXIT |
| CGEM CULLINAN THERAPEUTICS INC | 0.12% | 426,478 | $7.8M | EXIT |
| PHAT PHATHOM PHARMACEUTICALS INC | 0.09% | 532,000 | $5.8M | EXIT |
| COGT COGENT BIOSCIENCES INC | 0.07% | 121,082 | $4.7M | EXIT |
| AVTX AVALO THERAPEUTICS INC | 0.06% | 219,813 | $4.1M | EXIT |
| TWST TWIST BIOSCIENCE CORP | 0.06% | 36,812 | $3.8M | EXIT |
| BDSX BIODESIX INC | 0.04% | 108,694 | $2.5M | EXIT |
| CPIX CUMBERLAND PHARMACEUTICALS | 0.01% | 96,982 | $628.4K | EXIT |
| SRZNW SURROZEN INC-CW25 | 0.00% | 166,666 | $2.8K | EXIT |
SEC filings for Q3 2026
- 13F-HR 0001012975-26-001063 · accepted Nov 16, 2026, 21:09 UTC